Skip to main content

Market Overview

GW Pharmaceuticals' Epidyolex Wins EU Positive Opinion For Seizures Disorder

Share:
  • The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for GW Pharmaceuticals Plc's (NASDAQ: GWPH) Epidyolex (cannabidiol). It is an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC) for patients two years of age and older.
  • TSC is characterized by benign tumors that grow in the body's vital organs, including the brain, skin, heart, eyes, kidneys, and lungs, and in which epilepsy is the most common neurological feature.
  • The condition is typically diagnosed in childhood.
  • The EMA approved GW's cannabidiol oral solution in September 2019 as adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.
  • Price Action: GWPH is up 0.1% at $215.05 in market trading hours on the last check Friday.
 

Related Articles (GWPH)

View Comments and Join the Discussion!

Posted-In: European Commission Seizures DisorderBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com